Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with another multibillion-dollar deal, a word on the future of Sanofi, and a setback in one of medicine’s longest-running quests.
Sanofi reveals plan for 12 new blockbuster medicines
Sanofi has invited investors and analysts to a New York City hotel today, where the French drug giant will unveil a revamped pipeline and R&D strategy that aims to deliver 12 blockbuster medicines, each capable of generating $2 billion or more in sales.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect